What is raloxifene, and how does it work in two directions?
Raloxifene is a selective estrogen receptor modulator, or SERM: it behaves like estrogen in some tissues and blocks it in others. On bone it acts like estrogen and slows bone loss. On breast tissue it blocks estrogen, which is why it has a second, entirely separate role.
It is a 60 mg tablet taken once daily, with or without food. That dual behaviour is the whole basis for choosing it over a bisphosphonate: one drug addressing two problems in a woman who has both.
What does it do for bone, and what does it not?
The MORE trial enrolled 7,705 postmenopausal women with osteoporosis, mean age 66, and ran for three years. Raloxifene reduced vertebral fracture risk. The later RUTH trial, in 10,101 women followed for a median of 5.6 years, found a 35% reduction in clinical vertebral fractures.
What it has not been shown to do is reduce hip or other non-vertebral fractures. That single distinction decides most prescriptions, because hip fracture is the outcome with the heaviest consequences. A woman whose main risk is at the hip is usually better served by a bisphosphonate or denosumab. Our page on osteoporosis medications compared lays the options side by side.
It also does not build bone the way an anabolic agent does. It slows loss.
How large is the breast cancer effect?
In RUTH, raloxifene almost halved the risk of invasive breast cancer, an effect driven primarily by reduction in estrogen-receptor-positive disease. For a woman who has both thinning bone and a raised breast cancer risk, that double action is the main reason it gets chosen over a bisphosphonate.
Two caveats that belong in the same paragraph as the headline. It lowers the odds in women who already carry raised risk; it does not treat breast cancer, and it guarantees nothing. And it reduces ER-positive disease specifically, not every subtype. Our page on HRT and breast cancer risk covers how these risk conversations are usually framed.
What is the boxed warning, in actual numbers?
Raloxifene carries a boxed warning covering venous thromboembolism and death from stroke in women with coronary heart disease or at increased risk of major coronary events. The numbers behind the stroke half come from RUTH.
Among 10,101 women with or at increased coronary risk, followed a median of 5.6 years, fatal stroke occurred in 59 women on raloxifene against 39 on placebo (hazard ratio 1.49, 95% CI 1.00 to 2.24, P = .05). Overall stroke incidence was not significantly increased; the signal was in fatal strokes. Raloxifene did not significantly affect the risk of coronary events either way.
That is a real signal in a specific population: women already at increased coronary risk. It is the reason cardiovascular history is weighed before this drug is chosen, and why it is a poor fit for a woman whose main problem is cardiovascular rather than skeletal. See heart health in women.
How does it compare with the alternatives?
| Raloxifene | Bisphosphonate | Estrogen therapy | |
|---|---|---|---|
| Vertebral fracture | Reduced (35% in RUTH) | Reduced | Reduced |
| Hip fracture | Not shown | Reduced | Reduced |
| Hot flashes | Worsens | No effect | Improves |
| Breast cancer risk | Reduced in women at increased risk | No effect | Depends on regimen |
| Clot risk | Increased | No increase | Increased with oral, not shown with transdermal |
| Vaginal symptoms | No benefit | No effect | Improves |
Read across the hip fracture row first. It is the line that most often decides against raloxifene.
What is it like to take?
- Hot flashes. It commonly triggers or worsens them, which makes it a poor fit for a woman still in the thick of vasomotor symptoms. See hot flashes.
- Leg cramps. Common, harmless, and a frequent reason women stop.
- Prolonged immobility needs a plan. Surgery, bed rest and long flights concentrate clot risk. Stop before planned immobility as directed and move during long journeys.
- It does not treat vaginal dryness. Because it blocks estrogen in some tissues, genitourinary symptoms need separate local treatment. See vaginal estrogen.
- Calcium and vitamin D still matter. Raloxifene does not replace them; see calcium and vitamin D for bones.
Report promptly: swelling, pain or warmth in one leg, sudden breathlessness or chest pain, new vision changes, or any new fracture.
What can it not be used for?
Raloxifene has been studied specifically as a way to hold bone after stopping denosumab, and it does not work for that. It failed to control either the high bone turnover or the spontaneous vertebral fracture risk that follows denosumab withdrawal. If you are coming off denosumab, raloxifene is not the bridge, and our page on denosumab explains what is.
So who does it suit?
A postmenopausal woman whose fracture risk is mainly spinal rather than at the hip, who has elevated breast cancer risk, who is past the worst of her hot flashes, who has no clot history, and who is not at high coronary risk. Outside that profile another option is usually more appropriate.
There is no fixed course length. It is continued while the balance of spinal fracture risk, breast cancer risk reduction and clot and stroke risk still favours it, and that balance shifts with age as vascular risk rises. That makes it a treatment worth actively reviewing every year or two rather than repeating on autopilot. Our page on FRAX covers how fracture risk itself is estimated.
How does it compare with tamoxifen for breast risk?
Both are SERMs used for breast cancer risk reduction, and they behave differently outside the breast. Tamoxifen stimulates the endometrium and carries a uterine cancer signal; raloxifene does not stimulate the endometrium, which is one of its practical advantages in a woman with a uterus.
Against that, tamoxifen can be used before menopause while raloxifene is for postmenopausal women only. If breast risk reduction rather than bone is the main reason for treatment, that comparison belongs with whoever manages your breast risk rather than being settled by a bone conversation.
What does it do to your other blood results?
Raloxifene lowers LDL cholesterol modestly, without a demonstrated reduction in coronary events. That combination is worth knowing, because an improved lipid panel on this drug is not evidence that your cardiovascular risk fell. In RUTH, coronary events were unaffected either way while fatal strokes rose.
It does not raise triglycerides the way oral estrogen can, and it has no meaningful effect on the liver enzymes on a routine panel. Our page on reading a lipid panel covers why an isolated LDL improvement is weaker evidence than it looks.
What happens if you stop?
Protection stops with the drug. Bone density drifts back toward where it would otherwise have been, without the rebound overshoot that follows denosumab withdrawal, and without the reservoir effect that lets bisphosphonates keep working after the last tablet.
The breast risk reduction also ends. Neither effect persists, which is why the decision to continue is reviewed rather than assumed, and why our guide to stopping osteoporosis medication treats SERMs as their own category rather than lumping them with bisphosphonates.
Why is it prescribed less than it used to be?
Three reasons, and none of them is that it stopped working.
The hip fracture gap is the first: as bisphosphonates and denosumab accumulated evidence across all fracture types, a drug with vertebral-only benefit moved down the list for most women. The RUTH stroke signal is the second, since it arrived in a population many candidates belong to. And the third is simply that hot flashes make it intolerable for a large share of women in the years when osteoporosis treatment usually starts.
What survives is a specific niche rather than a general option, and knowing that you are in the niche is the useful part. It also means a prescriber suggesting it is likely doing so for a reason worth asking about: usually breast risk, an intact uterus, or a clot-free history combined with spinal rather than hip risk.
What does it cost and how is it taken?
It is available as a generic, which makes it among the cheaper options in this space, and it is a daily tablet with no timing requirements: with or without food, no need to stay upright, no fasting window. Compared with the oral bisphosphonate routine, that is a genuine practical advantage for women who found weekly tablets unworkable.
Adherence still matters, because protection stops when the tablets do. Our page on osteoporosis treatment covers where it sits in the sequence, and bone density testing covers how the response is monitored.